Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05335122 | A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT) | PHASE2 | COMPLETED | 83 | — | — | Mar 16, 2022 | Jan 24, 2025 | Mar 21, 2025 | 30 | United States |
IOP changes from baseline at 8AM, 10AM, and 4PM at Week 2, Week 6, and Week 12 in the study eye
| Arm | Type | Description |
|---|---|---|
| OTX-TIC Low Dose | EXPERIMENTAL | Travoprost Intracameral Implant low dose |
| OTX-TIC High Dose | EXPERIMENTAL | Travoprost Intracameral Implant high dose |
| Durysta | ACTIVE_COMPARATOR | Bimatoprost Intracameral Implant 10 µg |
| Name | Type | Description |
|---|---|---|
| OTX-TIC low dose Travoprost Intracameral Implant | DRUG | OTX-TIC implant is injected into the anterior chamber of the eye. |
| OTX-TIC high dose Travoprost Intracameral Implant | DRUG | OTX-TIC implant is injected into the anterior chamber of the eye. |
| Durysta, Bimatoprost Intracameral Implant 10 µg | DRUG | Durysta is injected into the anterior chamber of the eye. |
Inclusion Criteria: * Are 18 years of age or older at the time of screening * Provide written informed consent and are able to comply with all study requirements * Are willing to withhold glaucoma medications according to the study requirements, and in the opinion of the investigator can do so with...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |